{"protocolSection": {"identificationModule": {"nctId": "NCT01954121", "orgStudyIdInfo": {"id": "N01364"}, "organization": {"fullName": "UCB Pharma", "class": "INDUSTRY"}, "briefTitle": "Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures", "officialTitle": "An Open-label, Randomized, Parallel-group, Active-controlled Study Comparing the Efficacy and Safety of Levetiracetam to Carbamazepine Used as Monotherapy in Subjects Newly or Recently Diagnosed as Epilepsy and Partial-onset Seizures"}, "statusModule": {"statusVerifiedDate": "2017-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-09"}, "primaryCompletionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-09-26", "studyFirstSubmitQcDate": "2013-09-26", "studyFirstPostDateStruct": {"date": "2013-10-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-03-18", "resultsFirstSubmitQcDate": "2016-06-30", "resultsFirstPostDateStruct": {"date": "2016-08-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-07-06", "lastUpdatePostDateStruct": {"date": "2017-08-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "UCB Pharma SA", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese population with newly or recently diagnosed Epilepsy who are experiencing Partial-Onset Seizures (POS)."}, "conditionsModule": {"conditions": ["Epilepsy", "Partial Seizures"], "keywords": ["Levetiracetam", "Keppra", "Monotherapy", "China", "Epilepsy", "Partial-onset Seizures"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 436, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Levetiracetam", "type": "EXPERIMENTAL", "description": "Levetiracetam 1000 mg/day", "interventionNames": ["Drug: Levetiracetam"]}, {"label": "Carbamazepine", "type": "ACTIVE_COMPARATOR", "description": "Carbamazepine 400 mg/day", "interventionNames": ["Drug: Carbamazepine"]}], "interventions": [{"type": "DRUG", "name": "Levetiracetam", "description": "Immediate release film-coated tablets at strengths of 250 mg and 500 mg.\n\n* Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)\n* Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid\n* Down-titration Period (Week 30 up to Week 33)", "armGroupLabels": ["Levetiracetam"], "otherNames": ["Keppra"]}, {"type": "DRUG", "name": "Carbamazepine", "description": "Immediate release tablets at a strength of 200 mg.\n\n* Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)\n* Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid\n* Down-titration Period (Week 30 up to Week 33)", "armGroupLabels": ["Carbamazepine"], "otherNames": ["Tegretol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportion of Subjects Remaining Seizure Free During the 6-months Evaluation Period", "timeFrame": "6-months Evaluation Period (From Week 4 to Week 30)"}], "secondaryOutcomes": [{"measure": "Proportion of Subjects Retained in the Study for the Duration of the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period", "timeFrame": "From Week 1 to Week 30"}, {"measure": "Time to First Seizure or Discontinuation Due to an Adverse Event (AE) / Lack of Efficacy (LOE) During the Evaluation Period", "description": "Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.", "timeFrame": "From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)"}, {"measure": "Time to First Seizure During the Evaluation Period", "description": "Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.", "timeFrame": "From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)"}, {"measure": "Time to First Seizure During the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period From the First Dose of Study Drug", "description": "Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.", "timeFrame": "From Randomization (Week 1) up to Evaluation Visit (Week 30)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subject is of Chinese origin and \u2265 16 years of age\n* Subject is newly or recently diagnosed with Epilepsy, having experienced unprovoked Partial-Onset Seizures (POS)\n* Subject has experienced at least 2 unprovoked seizures in the year preceding randomization, of which at least 1 unprovoked seizure occurred in the 3 months preceding randomization\n* Subject has had an Electroencephalogram (EEG) and a brain Computed Tomography (CT) scan or brain Magnetic Resonance Imaging (MRI) scan consistent with a diagnosis of Epilepsy with POS\n\nExclusion Criteria:\n\n* Subject tests positive for human leukocyte antigen major histocompatibility complex, class I,B (HLA-B)\\* 1502 allele\n* Subject has a history or presence of seizures of other types than Partial-Onset Seizures (POS)\n* Subject has only experienced type IA nonmotor seizures\n* Subject has a history or presence of seizures occurring only in clustered patterns\n* Subject has a history of clinical or Electroencephalogram (EEG) findings suggestive of Idiopathic Generalized Epilepsy prior to randomization\n* Subject has current or previous diagnosis of pseudoseizures, conversion disorders, or other nonepileptic ictal events that could be confused with seizures\n* Subject has a history of Status Epilepticus", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "UCB Clinical Trial Call Center", "affiliation": "+1 877 822 9493 (UCB)", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "13", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "16", "city": "Changchun City", "country": "China"}, {"facility": "10", "city": "Chengdu", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "5", "city": "Chengdu", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "4", "city": "Chongqing", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "26", "city": "Guangzhou City", "country": "China"}, {"facility": "11", "city": "Guangzhou", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "1", "city": "Guangzhou", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "20", "city": "Guangzhou", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "24", "city": "Hangzhou", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "22", "city": "Harbin", "country": "China", "geoPoint": {"lat": 45.75, "lon": 126.65}}, {"facility": "29", "city": "Kunming", "country": "China", "geoPoint": {"lat": 25.03889, "lon": 102.71833}}, {"facility": "23", "city": "Nanjing City", "country": "China"}, {"facility": "6", "city": "Nanjing City", "country": "China"}, {"facility": "8", "city": "Nanjing City", "country": "China"}, {"facility": "21", "city": "Nanjing", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "27", "city": "Qingdao", "country": "China", "geoPoint": {"lat": 36.06488, "lon": 120.38042}}, {"facility": "14", "city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "15", "city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "18", "city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "2", "city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "19", "city": "Shijiazhuang", "country": "China", "geoPoint": {"lat": 38.04139, "lon": 114.47861}}, {"facility": "3", "city": "Suzhou", "country": "China", "geoPoint": {"lat": 31.30408, "lon": 120.59538}}, {"facility": "9", "city": "Taiyuan", "country": "China", "geoPoint": {"lat": 37.86944, "lon": 112.56028}}, {"facility": "25", "city": "Tianjin", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "12", "city": "Wuhan", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "7", "city": "Xi'an", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}, {"facility": "17", "city": "Xian", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "FDA Safety Alerts and Recalls", "url": "http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participant Flow refers to the Randomized Set which consists of all subjects who were randomized in this study.", "recruitmentDetails": "This study started to enroll subjects in China in September 2013.", "groups": [{"id": "FG000", "title": "Levetiracetam", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Levetiracetam (LEV) 250 mg bid. During Stabilization and Evaluation Period (27 weeks) LEV was taken bid 500 mg."}, {"id": "FG001", "title": "Carbamazepine-IR", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Carbamazepine immediate-release (CBZ-IR) 200 mg qd. During Stabilization and Evaluation (27 weeks) Period CBZ-IR was taken bid 200 mg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "220"}, {"groupId": "FG001", "numSubjects": "216"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "93"}, {"groupId": "FG001", "numSubjects": "125"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "127"}, {"groupId": "FG001", "numSubjects": "91"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "94"}, {"groupId": "FG001", "numSubjects": "41"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "12"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "AE, serious fatal", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "AE, non-serious non-fatal", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "22"}]}, {"type": "SAE, non-fatal", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Non-compliant with study procedures", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Non-compliant patient", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Subject did not follow instructions", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The Baseline Characteristics refers to the Safety Set (SS) which consists of all subjects who were randomized and received at least 1 dose of trial medication.", "groups": [{"id": "BG000", "title": "Levetiracetam (Safety Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Levetiracetam (LEV) 250 mg bid. During Stabilization and Evaluation Period (27 weeks) LEV was taken bid 500 mg."}, {"id": "BG001", "title": "Carbamazepine-IR (Safety Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Carbamazepine immediate-release (CBZ-IR) 200 mg qd. During Stabilization and Evaluation (27 weeks) Period CBZ-IR was taken bid 200 mg."}, {"id": "BG002", "title": "Total Title"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "218"}, {"groupId": "BG001", "value": "215"}, {"groupId": "BG002", "value": "433"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "42"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "184"}, {"groupId": "BG001", "value": "186"}, {"groupId": "BG002", "value": "370"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "21"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"title": "mean (standard deviation)", "categories": [{"measurements": [{"groupId": "BG000", "value": "37.8", "spread": "16.2"}, {"groupId": "BG001", "value": "33.3", "spread": "14.3"}, {"groupId": "BG002", "value": "35.6", "spread": "15.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "106"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "200"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "112"}, {"groupId": "BG001", "value": "121"}, {"groupId": "BG002", "value": "233"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Proportion of Subjects Remaining Seizure Free During the 6-months Evaluation Period", "populationDescription": "The Per Protocol Set consisted of all subjects in the Full Analysis Set who entered the Evaluation Period and who did not have any important protocol deviations determined to impact the interpretation of efficacy. Criteria that might impact the assessment of efficacy was determined during a Data Review Meeting before the database lock.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of subjects", "timeFrame": "6-months Evaluation Period (From Week 4 to Week 30)", "groups": [{"id": "OG000", "title": "Levetiracetam (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Levetiracetam (LEV) 250 mg bid. During Stabilization and Evaluation Period (27 weeks) LEV was taken bid 500 mg."}, {"id": "OG001", "title": "Carbamazepine-IR (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Carbamazepine immediate-release (CBZ-IR) 200 mg qd. During Stabilization and Evaluation (27 weeks) Period CBZ-IR was taken bid 200 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "171"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "47.3"}, {"groupId": "OG001", "value": "68.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The adjusted absolute difference in treatment group seizure-free proportions (referenced as 'Adjusted difference in proportions' in 'Method of Estimation' below) was derived from the adjusted treatment group proportions of seizure-free subjects. The adjusted proportions were derived from a logistic regression model of seizure freedom using treatment and the categories for the number of seizures in the 3-month period prior to Visit 1 (\u22642 seizures and \\>2 seizures) as covariates.", "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "The non-inferiority margin for the adjusted difference in seizure free proportion in the LEV minus the seizure free proportion in the CBZ-IR group was set to absolute -20% points.", "paramType": "adjusted difference in proportions", "paramValue": "-22.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.1", "ciUpperLimit": "-12.6"}]}, {"type": "SECONDARY", "title": "Proportion of Subjects Retained in the Study for the Duration of the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period", "populationDescription": "The Per Protocol Set consisted of all subjects in the Full Analysis Set who entered the Evaluation Period and who did not have any important protocol deviations determined to impact the interpretation of efficacy. Criteria that might impact the assessment of efficacy was determined during a Data Review Meeting before the database lock.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of subjects", "timeFrame": "From Week 1 to Week 30", "groups": [{"id": "OG000", "title": "Levetiracetam (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Levetiracetam (LEV) 250 mg bid. During Stabilization and Evaluation Period (27 weeks) LEV was taken bid 500 mg."}, {"id": "OG001", "title": "Carbamazepine-IR (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Carbamazepine immediate-release (CBZ-IR) 200 mg qd. During Stabilization and Evaluation (27 weeks) Period CBZ-IR was taken bid 200 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "171"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "48.4"}, {"groupId": "OG001", "value": "70.2"}]}]}]}, {"type": "SECONDARY", "title": "Time to First Seizure or Discontinuation Due to an Adverse Event (AE) / Lack of Efficacy (LOE) During the Evaluation Period", "description": "Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.", "populationDescription": "The Per Protocol Set consisted of all subjects in the Full Analysis Set who entered the Evaluation Period and who did not have any important protocol deviations determined to impact the interpretation of efficacy. Criteria that might impact the assessment of efficacy was determined during a Data Review Meeting before the database lock.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events", "timeFrame": "From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)", "groups": [{"id": "OG000", "title": "Levetiracetam (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Levetiracetam (LEV) 250 mg bid. During Stabilization and Evaluation Period (27 weeks) LEV was taken bid 500 mg."}, {"id": "OG001", "title": "Carbamazepine-IR (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Carbamazepine immediate-release (CBZ-IR) 200 mg qd. During Stabilization and Evaluation (27 weeks) Period CBZ-IR was taken bid 200 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "171"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88"}, {"groupId": "OG001", "value": "45"}]}]}]}, {"type": "SECONDARY", "title": "Time to First Seizure During the Evaluation Period", "description": "Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.", "populationDescription": "The Per Protocol Set consisted of all subjects in the Full Analysis Set who entered the Evaluation Period and who did not have any important protocol deviations determined to impact the interpretation of efficacy. Criteria that might impact the assessment of efficacy was determined during a Data Review Meeting before the database lock.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events", "timeFrame": "From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)", "groups": [{"id": "OG000", "title": "Levetiracetam (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Levetiracetam (LEV) 250 mg bid. During Stabilization and Evaluation Period (27 weeks) LEV was taken bid 500 mg."}, {"id": "OG001", "title": "Carbamazepine-IR (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Carbamazepine immediate-release (CBZ-IR) 200 mg qd. During Stabilization and Evaluation (27 weeks) Period CBZ-IR was taken bid 200 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "171"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87"}, {"groupId": "OG001", "value": "39"}]}]}]}, {"type": "SECONDARY", "title": "Time to First Seizure During the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period From the First Dose of Study Drug", "description": "Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.", "populationDescription": "The Per Protocol Set consisted of all subjects in the Full Analysis Set who entered the Evaluation Period and who did not have any important protocol deviations determined to impact the interpretation of efficacy. Criteria that might impact the assessment of efficacy was determined during a Data Review Meeting before the database lock.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "events", "timeFrame": "From Randomization (Week 1) up to Evaluation Visit (Week 30)", "groups": [{"id": "OG000", "title": "Levetiracetam (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Levetiracetam (LEV) 250 mg bid. During Stabilization and Evaluation Period (27 weeks) LEV was taken bid 500 mg."}, {"id": "OG001", "title": "Carbamazepine-IR (Per Protocol Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Carbamazepine immediate-release (CBZ-IR) 200 mg qd. During Stabilization and Evaluation (27 weeks) Period CBZ-IR was taken bid 200 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "186"}, {"groupId": "OG001", "value": "171"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "57"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse Events (AEs) were collected from Visit 1 (Week 0) until Safety Follow Up Visit (Week 35).", "description": "Adverse Events refer to the Safety Set (SS), which is a subset of the Randomized Set and consisted of all subjects who received at least 1 dose of study medication after randomization, either Levetiracetam or Carbamezepine immediate-release.", "eventGroups": [{"id": "EG000", "title": "Levetiracetam (Safety Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Levetiracetam (LEV) 250 mg bid. During Stabilization and Evaluation Period (27 weeks) LEV was taken bid 500 mg.", "seriousNumAffected": 9, "seriousNumAtRisk": 218, "otherNumAffected": 92, "otherNumAtRisk": 218}, {"id": "EG001", "title": "Carbamazepine-IR (Safety Set)", "description": "During the Up-Titration period (2 weeks), subjects initiated treatment at half the randomized target dose with Carbamazepine immediate-release (CBZ-IR) 200 mg qd. During Stabilization and Evaluation (27 weeks) Period CBZ-IR was taken bid 200 mg.", "seriousNumAffected": 11, "seriousNumAtRisk": 215, "otherNumAffected": 93, "otherNumAtRisk": 215}], "seriousEvents": [{"term": "Thrombocytopenic purpura", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Peripheral swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Lung infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Brain contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}]}, {"term": "Burns third degree", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}]}, {"term": "Epidural haemorrhage", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}]}, {"term": "Hand fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Rib Fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}]}, {"term": "Breast cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Status epilepticus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}]}, {"term": "Subarachnoid haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}]}, {"term": "Memory impairment", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Menopausal symptoms", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 215}]}, {"term": "Drug eruption", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Rash", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 215}]}, {"term": "Abortion induced", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 215}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 48, "numAffected": 40, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 42, "numAffected": 32, "numAtRisk": 215}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 12, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 18, "numAffected": 16, "numAtRisk": 215}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 11, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 215}]}, {"term": "Blood cholesterol increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 215}]}, {"term": "Gamma-glutamyltransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 11, "numAffected": 11, "numAtRisk": 215}]}, {"term": "White blood cell count decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 14, "numAffected": 11, "numAtRisk": 215}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 48, "numAffected": 33, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 29, "numAffected": 18, "numAtRisk": 215}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 25, "numAffected": 20, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 8, "numAffected": 7, "numAtRisk": 215}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA18.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 33, "numAffected": 19, "numAtRisk": 218}, {"groupId": "EG001", "numEvents": 47, "numAffected": 16, "numAtRisk": 215}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "UCB (Study Director)", "organization": "UCB Cares", "phone": "+1 887 822 9493"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}, {"id": "D000012640", "term": "Seizures"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}, {"id": "D000009461", "term": "Neurologic Manifestations"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M15452", "name": "Seizures", "asFound": "Seizures", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}, {"id": "M12404", "name": "Neurologic Manifestations", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000002220", "term": "Carbamazepine"}, {"id": "D000077287", "term": "Levetiracetam"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000018697", "term": "Nootropic Agents"}, {"id": "D000018692", "term": "Antimanic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000018712", "term": "Analgesics, Non-Narcotic"}, {"id": "D000000700", "term": "Analgesics"}, {"id": "D000018689", "term": "Sensory System Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000026941", "term": "Sodium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000065701", "term": "Cytochrome P-450 CYP3A Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}], "browseLeaves": [{"id": "M1741", "name": "Levetiracetam", "asFound": "Deliver", "relevance": "HIGH"}, {"id": "M5480", "name": "Carbamazepine", "asFound": "Lymph node dissection", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M20774", "name": "Nootropic Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M4032", "name": "Analgesics", "relevance": "LOW"}, {"id": "M20786", "name": "Analgesics, Non-Narcotic", "relevance": "LOW"}, {"id": "M23177", "name": "Sodium Channel Blockers", "relevance": "LOW"}, {"id": "M30025", "name": "Diuretics, Potassium Sparing", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "NootAg", "name": "Nootropic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "Analg", "name": "Analgesics"}, {"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}]}}, "hasResults": true}